South African-based JSE Limited listed Aspen continues to increase the number of lives benefiting from its products, reaching more than 150 countries across the world. The extensive basket of Aspen products provides treatment for a broad spectrum of acute and chronic conditions experienced throughout all stages of life.
Aspen is represented in South Africa, Australia, Hong Kong, Malaysia, Philippines, Taiwan, Japan, Kenya, Nigeria, Tanzania, Uganda, Ireland, United Arab Emirates, Germany, the Netherlands, Mauritius, Brazil, Mexico, Venezuela and the United States of America. Acquisitions announced in 2013 will further extend the Group’s emerging market presence to the Commonwealth of Independent States, comprising Russia and the former Soviet Republics as well as to Central and Eastern Europe. The Group has 23 manufacturing facilities at 17 sites on 6 continents and approximately 8200 employees.
Aspen is now a significant global pharma company, supplying branded and generic pharmaceuticals in more than 150 countries across the world. It was founded by Stephen Saad less than 15 years ago. It has a Market Cap of R125.9 billion, a PE of 32.9 and a dividend yield of 0.5%. David Lerche from Avior Research. Host Bronwyn Nielsen and resident expert Paul Theron from Vestact decide whether Aspen is hot or not.